

Title

PERSISTENCE OF SIGNS AND SYMPTOMS IN TREATED PATIENTS WITH IgAN: EVIDENCE FROM REAL-WORLD DATA

Authors/affiliations

Richard Lafayette¹, Michel Kroes², Carolina Aldworth³, Luis Prieto Rodriguez², Aneesh Thomas George⁴, Weijia Wang³, Jonathan de Courcy⁵, Keisha Golden⁵, Emma Chatterton⁵, Li Yao⁶, Dario Roccatello⁷

Affiliations: ¹Stanford University Medical Center, United States; ²Novartis Pharma AG, Basel, Switzerland; ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States; ⁴Novartis Healthcare Private Limited, Hyderabad, India; ⁵Adelphi Real World, Bollington, England, United Kingdom; ⁶The First Hospital of China Medical University, Shenyang, PR China; ⁷University of Turin, Turin, Italy

Introduction

Immunoglobulin A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, with an estimated annual incidence of 25 per million. It currently has limited treatment options. This analysis aimed to describe IgAN signs and symptoms (S&S) in treated patients.

Methods

The Adelphi IgAN Disease Specific Programme was a point-in-time survey of IgAN-treating nephrologists in the US, EU5 (France, Germany, Italy, Spain, UK) and Asia (China and Japan) between June and October 2021. Nephrologists completed structured online records for successive patients presenting with IgAN, including patient's demographics, IgAN treatment history, and a list of 29 current S&S.

Results

295 nephrologists completed records for 1376 patients treated for a minimum of one week at time of survey. Mean patient age was 42.6 years, 59% were men. Median time since treatment initiation was 86 weeks (US 61, EU5 121, Asia 76).

Despite treatment with standard of care (ACEi, ARB, Statins, Corticosteroids), most patients presented with S&S at time of survey. This was consistent in patients with a longer treatment duration. Common S&S experienced were proteinuria, hematuria, hypertension, and fatigue (**Table 1**).

A higher proportion of patients in their second year of treatment were at a better CKD stage than those in their first year of treatment, or those treated for >2 years.

Of those patients treated for more than two years, US 26%, EU5 31%, Asia 24% had >1g proteinuria/day where reported.

Conclusion

Despite treatment, IgAN S&S persist in the majority of patients. Proteinuria persists in many patients increasing risk of progression to kidney failure. This shows a need for better treatment options for IgAN.

This abstract was first submitted to American Society of Nephrology (ASN) Kidney Week 2022 congress. Authors received permission from ASN congress to submit it as encore abstract in WCN congress by providing proper attribution. **Citation:** Lafayette RA, Kroes M, Aldworth CA, Rodriguez LP, George AT, de

Courcy JJ, Golden KJ, Chatterton E, Yao L, Roccatello D: SA-PO657: Persistence of Signs and Symptoms in Treated Patients With IgA Nephropathy: Evidence From Real-World Data [Abstract]. J Am Soc Nephrol 33, 2022: Page.784

Table 1	US				EU5				Asia			
	Any n=232	<1y n=105	1-2y n=50	>2 y n=77	Any n=474	<1y n=139	1-2y n=82	>2 y n=253	Any n=670	<1y n=258	1-2y n=125	>2 y n=287
Time since treatment initiation (Years)												
Number of signs & symptoms Mean (SD)	2.2 (2.4)	2.6 (2.4)	2.0 (2.4)	2.0 (2.5)	1.8 (1.8)	2.1 (1.9)	1.9 (1.6)	1.6 (1.8)	2.6 (2.5)	2.6 (2.4)	2.2 (2.2)	2.7 (2.7)
% Currently symptomatic	78%	80%	78%	75%	75%	80%	79%	72%	79%	83%	75%	76%
Top 10 signs & symptoms												
Proteinuria	45%	50%	46%	38%	36%	41%	33%	34%	54%	60%	53%	49%
Hematuria	30%	34%	28%	26%	20%	24%	16%	19%	30%	31%	25%	31%
Hypertension	27%	36%	18%	21%	28%	32%	33%	25%	22%	17%	15%	28%
Fatigue	22%	28%	16%	18%	16%	19%	20%	12%	22%	21%	23%	24%
Edema in extremities	16%	17%	8%	18%	9%	14%	6%	8%	18%	22%	11%	18%
High cholesterol	20%	27%	10%	17%	14%	13%	15%	14%	8%	10%	5%	9%
Discolored urine	7%	8%	4%	8%	5%	5%	6%	5%	17%	23%	11%	13%
Sleep problems	7%	7%	6%	9%	7%	5%	10%	7%	9%	8%	10%	10%
Pain in abdomen	4%	3%	10%	1%	5%	6%	7%	4%	11%	5%	10%	17%
Oliguria	1%	1%	2%	0%	4%	7%	1%	3%	9%	12%	2%	8%
Current GFR												
GFR ≥45 mL/min/1.73 m ²	71%	68%	76%	71%	74%	73%	80%	74%	82%	89%	91%	72%
GFR <45 mL/min/1.73 m ²	29%	32%	24%	29%	26%	27%	20%	26%	18%	11%	9%	28%
Current Proteinuria (where reported)												
	n=209	n=90	n=45	n=74	n=420	n=121	n=71	n=228	n=627	n=238	n=120	n=269
>1g/day	37%	48%	36%	26%	37%	47%	41%	31%	24%	29%	16%	24%
≤1g/day	63%	52%	64%	74%	63%	53%	59%	69%	76%	71%	84%	76%